Masimo (MASI)
(Delayed Data from NSDQ)
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 7:00 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 7:00 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
PacBio's (PACB) New Offering to Enable High-Throughput Workflows
by Zacks Equity Research
PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.
Baxter's (BAX) New Premix Drug Now Available in the U.S.
by Zacks Equity Research
Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
HealthEquity (HQY) New Tie Up to Meet Clients' Healthcare Needs
by Zacks Equity Research
HealthEquity's (HQY) latest collaboration is expected to enhance digital transformation with Microsoft Azure and build better experiences for customers and employees.
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Philips (PHG) Inks 7-Year Partnership With Northwell Health
by Zacks Equity Research
Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.
Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.
Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
Masimo (MASI) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study
by Zacks Equity Research
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.
Masimo (MASI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) Patient Monitoring Devices Favored by New Study
by Zacks Equity Research
Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.
Masimo (MASI) Expands Partnership with Philips for W1 Watch
by Zacks Equity Research
Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit
by Zacks Equity Research
A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.
UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?
by Zacks Equity Research
An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.